Introduction
Percutaneous edge-to-edge therapy for mitral regurgitation (MR) was first introduced in 2003 and was successfully being performed 2 years later. 1 Since then, this therapy has become a well-established treatment option for patients suffering from symptomatic, severe MR who are not eligible for surgery. Recent guidelines recommend percutaneous procedures for primary and secondary MR in high surgical risk or inoperable patients. 2 To date, more than 45 000 procedures are documented to have been performed, with comparable mortality results when compared with surgical treatment. 3 Learning points
• Diseases that result in a pressure or volume overloaded left heart may favour iatrogenic atrial septal defect persistence following percutaneous edge-to-edge mitral valve repair.
• Close follow-up including medical history, physical examinations, and meaningful multimodal imaging can lead to successful diagnosis and treatment.
• The sequence of structural interventions in multivalvular disease should be strictly based on a good understanding of haemodynamic conditions and possible treatment-related consequences.
. The intraprocedural puncture of the interatrial septum causes an iatrogenic atrial septal defect (iASD), which usually closes spontaneously. However, some iASDs persist and become haemodynamically relevant, ultimately requiring interventional closure.
Timeline Case summary
In March 2017, an 83-year-old Caucasian woman presented herself to the emergency department with a 2 week history of progressive orthopnoea and peripheral oedema. The patient's current medications, including heart insufficiency therapeutics, i.e. beta-blockers (metoprolol), sartane (candesartan) and spironolactone, as well as diuretics (torasemide), bronchodilatators (salbutamol), and oral anticoagulation (phenprocoumon), had been taken regularly without interruption. The patient had an extensive medical history, including coronary artery disease with several previous coronary treatments, mixed severe pulmonary hypertension due to secondary right heart pressure and chronic obstructive pulmonary disease, and advanced multivalvular disease. The medical history was reprocessed as follows.
Two years prior to this presentation, transcatheter edge-to-edge mitral valve repair was performed due to severe symptomatic secondary MR and high surgical risk according to the heart team's assessment. Four months after successful transcatheter mitral valve repair, routine cardiac magnetic resonance imaging (CMR) was performed after the MitraClip therapy already presented dilatation of the right atrium (diameter, 48 mm; area, 3.44 cm ) with a reduced right ventricular EF of 37.5% (Figure 3) . 4 The Qp/Qs ratio was calculated as 1.5 at this time. We discussed this case thoroughly during the heart team's meeting and observed the cardiac decompensation in the context of a long-underestimated aortic valve disease. The heart team speculated that the shunt would remain at this severity after transfemoral transcatheter valve implantation, which took place 2 months before the third rehospitalization with dyspnoea and peripheral oedema in March 2017. In March 2017, physical examination revealed a normotensive brachial blood pressure (116/58 mmHg), irregular mild tachycardia, and moderate peripheral oedema, as well as signs of pulmonary congestion. Peripheral oxygen saturation was measured as 89%, in line with the symptoms of orthopnoea. No history of chest pain was indicated by the patient, and there was no evidence of advanced abnormal heart sounds. Blood examination revealed acute-on-chronic renal failure with an increased creatinine level of 1.5 mg/dL (range <0.9 mg/dL) and an increased international normalized ratio of 4.1 (range 0.9-1.1; target 2.5-3.0) under therapy with phenprocoumon. Electrocardiography showed tachycardia with known atrial fibrillation (108 b.p.m.), which was already under frequency-normalized treatment. Transthoracic echocardiography showed reduced right heart function with dilatation of the right ventricle (mid-cavitary diameter, 42 mm; tricuspid annular plane systolic excursion, 14 mm), severe tricuspid valve insufficiency, and inferior vena cava enlargement. Chest X-ray confirmed pleural effusions on both sides, which were treated conservatively by advanced diuretic therapy (conversion to temporary higher doses of i.v. furosemide) and improved heart insufficiency therapy (intensification of metoprolol and sartane therapy). Mixed (pre-and post-capillary) pulmonary hypertension was confirmed during right heart catheterization [PAsys 68 mmHg; PAWP (wedge pressure) 21 mmHg, PVR >3 WE 'Wood-Units']. Taking these medical findings together, the leading diagnosis was symptomatic right heart failure with associated impairments. The subsequent investigations after rehospitalization showed good results concerning the particular valvular treatments but also revealed a haemodynamically relevant iASD. As detected by transoesophageal echocardiography (TOE), the iASD now had a progressive left-to-right shunt, and duplex echocardiography revealed that it had nearly doubled in size, with a median diameter of 13.1 mm (Figure 4) . Due to the increased size and advanced secondary right heart failure, interventional closure of the iASD was indicated. Interventional closure with a 22-mm ASD occluder was successful. The patient recovered quickly, and no rehospitalization has occurred thus far. According to her outpatient cardiologist, the patient was in good clinical condition in October 2017. 
Discussion
Transcatheter edge-to-edge mitral valve repair has become an elegant therapeutic option for severe, symptomatic MR in patients not eligible for surgical therapy. As the number of treated patients increases, the side effects and their influence on outcome need to receive more attention to help anticipate which patients may be at risk and should thus be followed more closely.
In a meta-analysis, Alkhouli et al. 6 presented the incidence of persistent iASDs after transseptal puncture as 15%. A recent analysis showed an even higher incidence of iASDs of 23% after edge-to-edge mitral valve repair, as well as higher rehospitalization rates. 7 Estimation of the haemodynamic relevance of iASDs has been performed with transthoracic echocardiography or TOE in most published studies. 8, 9 Considering right ventricular function, volume and dimension, as well as recent guidelines, CMR is the method of choice and provides additional information for shunt quantification. 5 In our case report, the combination of TOE and CMR, as leading cardiac imaging techniques, allowed precise monitoring of right ventricular function and dimension. Although increased left heart pressure due to pLFLG-AS was successfully treated with transcatheter aortic valve implantation after edge-to-edge mitral valve repair, the iASD and right heart function worsened. However, interventional iASD closure was finally performed, and no further hospitalization has been documented. This case clearly demonstrates the possible development of a haemodynamically relevant iASD after transseptal puncture caused by remaining left heart-sided diseases, such as aortic valve stenosis. Our report not only highlights the importance of combining imaging techniques to detect haemodynamically relevant iASDs after edgeto-edge mitral valve repair but also emphasises focusing on patients who might be at a higher risk for worse outcomes. Furthermore, this case presentation shows the importance of correctly assessing valvular disease severity, especially under altered stroke volume conditions, in the context of a meaningful structural intervention sequence.
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